title: MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.
abstract: MHC class II expression defects have been evidenced in several human tumor cell lines originating from lung cancers or retinoblastoma. Accordingly, the mouse adenocarcinoma and fibrosarcoma cell lines, RAG and L(tk-), do not express I-A and I-E molecules even when treated with IFN-gamma. Here we show that fusion of both cell lines restores the inducible expression of MHC class II, thereby demonstrating that they present different and recessive alterations outside the MHC class II locus. CIITA, the MHC class II transactivator, controls the tissue-specific expression of MHC class II genes and creates the architecture of the transcriptional complex that binds to the MHC class II gene promoters. In L(tk-) cells, C2ta transcripts, expressed from the gene encoding CIITA, were indeed detected in severely limited amounts, with a defect in C2ta transcription initiation. In agreement we show here that the L(tk-) cell line does not express the CIITA protein. In contrast, in the RAG cell line, C2ta transcripts were expressed at normal levels, from the proper initiation site. The nucleotide sequencing of the CIITA cDNA from RAG did not reveal any mutation. However, the CIITA protein was not detected. These data evidence a new type of defect in a MHC class II-defective tumor cell line, as we show here that the alteration in the RAG cells occurs downstream of C2ta transcription. The RAG mutation might therefore reside in the C2ta transcript nuclear export or translation, or in the stability of the CIITA protein.
authors.affiliation: Departamento de Biologia, Facultad de Ciencias, Universidad de Chile, and Millennium Institute for Fundamental and Applied Biology, Casilla 653, Santiago, Chile.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Naves
authors.forename: Ana Maria
authors.initials: AM
authors.lastname: Lennon
authors.forename: Giovanna
authors.initials: G
authors.lastname: Barbieri
authors.forename: Lilian
authors.initials: L
authors.lastname: Reyes
authors.forename: Gisella
authors.initials: G
authors.lastname: Puga
authors.forename: Laura
authors.initials: L
authors.lastname: Salas
authors.forename: Virginie
authors.initials: V
authors.lastname: Deffrennes
authors.forename: Mario
authors.initials: M
authors.lastname: Rosemblatt
authors.forename: Marc
authors.initials: M
authors.lastname: Fellous
authors.forename: Dominique
authors.initials: D
authors.lastname: Charron
authors.forename: Catherine
authors.initials: C
authors.lastname: Alcaïde-Loridan
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Bono
mesh_terms: D000818:Animals; D001483:Base Sequence; D002478:Cells, Cultured; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D051379:Mice; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism; D009687:Nuclear Proteins; D011401:Promoter Regions, Genetic; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D015534:Trans-Activators / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D014157:Transcription Factors / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D000949:Histocompatibility Antigens Class II; C083728:MHC class II transactivator protein; D009687:Nuclear Proteins; D015534:Trans-Activators; D014157:Transcription Factors; D007371:Interferon-gamma